cargo-tx.com (CRGX): Utang marang Ekuitas

The market price visualization for CARGO Therapeutics (CRGX) demonstrates a debt-to-equity ratio of 0.00, highlighting the risks associated with a narrow specialization in CAR-T therapies for lymphomas. The business relies on a unique platform to combat tumor resistance, ensuring pricing power. The development of innovative treatment methods is based on synergy with leading scientific centers and academic laboratories.

CRGX: Rasio Total Utang marang Ekuitas CARGO Therapeutics, Inc. 21.02.2024 - 30.08.2025

Rincian metrik komprehensif lan analitis CARGO Therapeutics, Inc (CRGX)

- rega lan prakiraan konsensus rega:

Bagan rega CARGO Therapeutics, Inc.|CRGX - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Nilai pasar CARGO Therapeutics|CRGX - Nilai Bisnis

- rincian nilai buku perusahaan:

Nilai Buku saben Saham CARGO Therapeutics|CRGX - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku cargo-tx.com|CRGX - Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Utang marang Ekuitas CARGO Therapeutics|CRGX - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas CARGO Therapeutics|CRGX - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku CARGO Therapeutics|CRGX - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan CARGO Therapeutics|Indikator likuiditas cepet cargo-tx.com

- informasi bathi lan kelipatan valuasi:

CRGX - Bathi pungkasan

Analisis fundamental perusahaan:CARGO Therapeutics, Inc., CRGX

The organic expansion of the CARGO Therapeutics (CRGX) clinical trial center network without external alliances minimizes the need for debt financing. By analyzing the current leverage ratio (total debt to equity), an investor assesses the proportion of liabilities relative to equity; a low value for this metric confirms the business's financial autonomy and the absence of risks associated with excessive leverage during a period of inflation.

Pesaing CARGO Therapeutics (CRGX)